This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Choice of Stents and End Points for Treatment of De Novo Coronary Artery Lesions

Sorin J. Brener, MD

JAMA. 2006;295:937-938.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of JAMA, Morice and colleagues¹ present the results of the much anticipated REALITY trial, a prospective, randomized, nonblinded (operator) comparison of the sirolimus-eluting stent and the paclitaxel-eluting stent in patients with de novo coronary artery disease. Among the 1353 patients enrolled, nearly a third had diabetes mellitus, 40% had a previous infarction, and one quarter presented with unstable angina. The study protocol called for the randomization of 1 or 2 lesions (38% of patients) in (surprisingly) relatively small vessels (mean, 2.4 mm) to paclitaxel-eluting stent or sirolimus-eluting stent with independently conducted angiographic and clinical follow-up at 8 and 12 months, respectively. Of note, more than 90% of the patients returned for angiographic follow-up, an unusually high rate for this kind of trial.

With respect to the primary end point of the trial, there was no statistically significant difference in the incidence of . . . [Full Text of this Article]

Author Affiliation: Department of Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial
Marie-Claude Morice, Antonio Colombo, Bernhard Meier, Patrick Serruys, Corrado Tamburino, Giulio Guagliumi, Eduardo Sousa, Hans-Peter Stoll, and for the REALITY Trial Investigators
JAMA. 2006;295(8):895-904.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Drug-eluting stent thrombosis in patients undergoing non-cardiac surgery: is it always a problem?
Godet et al.
Br J Anaesth 2008;100:472-477.
ABSTRACT | FULL TEXT  

Multislice Computed Tomography After Left Main Drug-Eluting Stenting: Are We Putting the CarT Before the Horse?
Kimmelstiel
Circulation 2006;114:616-619.
FULL TEXT  

Sirolimus vs. Paclitaxel Stents: Little Difference in REALITY
Journal Watch Cardiology 2006;2006:3-3.
FULL TEXT